Login to Your Account

Exelixis speeds toward cabo decisions, adding positive OS data to mix

By Michael Fitzhugh
Staff Writer

Monday, February 1, 2016

Exelixis Inc. added increased overall survival vs. Afinitor to the list of benefits provided by cabozantinib for second-line renal cell carcinoma patients, providing what president and CEO Michael Morrissey told BioWorld Today was “the missing piece of the puzzle in terms of the full cabozantinib second line RCC story.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription